Cargando…

The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance

Tumor drug resistance is a multifactorial and heterogenous condition that poses a serious burden in clinical oncology. Given the increasing incidence of resistant tumors, further understanding of the mechanisms that make tumor cells able to escape anticancer drug effects is pivotal for developing ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Zippoli, Mara, Ruocco, Anna, Novelli, Rubina, Rocchio, Francesca, Miscione, Martina Sara, Allegretti, Marcello, Cesta, Maria Candida, Amendola, Pier Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800989/
https://www.ncbi.nlm.nih.gov/pubmed/36591453
http://dx.doi.org/10.3389/fonc.2022.947183
_version_ 1784861406238081024
author Zippoli, Mara
Ruocco, Anna
Novelli, Rubina
Rocchio, Francesca
Miscione, Martina Sara
Allegretti, Marcello
Cesta, Maria Candida
Amendola, Pier Giorgio
author_facet Zippoli, Mara
Ruocco, Anna
Novelli, Rubina
Rocchio, Francesca
Miscione, Martina Sara
Allegretti, Marcello
Cesta, Maria Candida
Amendola, Pier Giorgio
author_sort Zippoli, Mara
collection PubMed
description Tumor drug resistance is a multifactorial and heterogenous condition that poses a serious burden in clinical oncology. Given the increasing incidence of resistant tumors, further understanding of the mechanisms that make tumor cells able to escape anticancer drug effects is pivotal for developing new effective treatments. Neutrophils constitute a considerable proportion of tumor infiltrated immune cells, and studies have linked elevated neutrophil counts with poor prognosis. Tumor-associated neutrophils (TANs) can acquire in fact immunoregulatory capabilities, thus regulating tumor progression and resistance, or response to therapy. In this review, we will describe TANs’ actions in the tumor microenvironment, with emphasis on the analysis of the role of interleukin-8 (IL-8) and extracellular vesicles (EVs) as crucial modulators and mediators of TANs biology and function in tumors. We will then discuss the main mechanisms through which TANs can induce drug resistance, finally reporting emerging therapeutic approaches that target these mechanisms and can thus be potentially used to reduce or overcome neutrophil-mediated tumor drug resistance.
format Online
Article
Text
id pubmed-9800989
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98009892022-12-31 The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance Zippoli, Mara Ruocco, Anna Novelli, Rubina Rocchio, Francesca Miscione, Martina Sara Allegretti, Marcello Cesta, Maria Candida Amendola, Pier Giorgio Front Oncol Oncology Tumor drug resistance is a multifactorial and heterogenous condition that poses a serious burden in clinical oncology. Given the increasing incidence of resistant tumors, further understanding of the mechanisms that make tumor cells able to escape anticancer drug effects is pivotal for developing new effective treatments. Neutrophils constitute a considerable proportion of tumor infiltrated immune cells, and studies have linked elevated neutrophil counts with poor prognosis. Tumor-associated neutrophils (TANs) can acquire in fact immunoregulatory capabilities, thus regulating tumor progression and resistance, or response to therapy. In this review, we will describe TANs’ actions in the tumor microenvironment, with emphasis on the analysis of the role of interleukin-8 (IL-8) and extracellular vesicles (EVs) as crucial modulators and mediators of TANs biology and function in tumors. We will then discuss the main mechanisms through which TANs can induce drug resistance, finally reporting emerging therapeutic approaches that target these mechanisms and can thus be potentially used to reduce or overcome neutrophil-mediated tumor drug resistance. Frontiers Media S.A. 2022-12-16 /pmc/articles/PMC9800989/ /pubmed/36591453 http://dx.doi.org/10.3389/fonc.2022.947183 Text en Copyright © 2022 Zippoli, Ruocco, Novelli, Rocchio, Miscione, Allegretti, Cesta and Amendola https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zippoli, Mara
Ruocco, Anna
Novelli, Rubina
Rocchio, Francesca
Miscione, Martina Sara
Allegretti, Marcello
Cesta, Maria Candida
Amendola, Pier Giorgio
The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance
title The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance
title_full The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance
title_fullStr The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance
title_full_unstemmed The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance
title_short The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance
title_sort role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800989/
https://www.ncbi.nlm.nih.gov/pubmed/36591453
http://dx.doi.org/10.3389/fonc.2022.947183
work_keys_str_mv AT zippolimara theroleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT ruoccoanna theroleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT novellirubina theroleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT rocchiofrancesca theroleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT miscionemartinasara theroleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT allegrettimarcello theroleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT cestamariacandida theroleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT amendolapiergiorgio theroleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT zippolimara roleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT ruoccoanna roleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT novellirubina roleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT rocchiofrancesca roleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT miscionemartinasara roleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT allegrettimarcello roleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT cestamariacandida roleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance
AT amendolapiergiorgio roleofextracellularvesiclesandinterleukin8inregulatingandmediatingneutrophildependentcancerdrugresistance